Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients

por Laé, M., Couturier, J., Oudard, S., Radvanyi, F., Beuzeboc, P., Vieillefond, A.
Publicado 2010

Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay

por Mouttet, D., Laé, M., Caly, M., Gentien, D., Carpentier, S., Peyro-Saint-Paul, H., Vincent-Salomon, A., Rouzier, R., Sigal-Zafrani, B., Sastre-Garau, X., Reyal, F.
Publicado 2016

High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies

por Bollet, M A, Savignoni, A, Pierga, J-Y, Lae, M, Fourchotte, V, Kirova, Y M, Dendale, R, Campana, F, Sigal-Zafrani, B, Salmon, R, Fourquet, A, Vincent-Salomon, A
Publicado 2008

HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?

por Vincent-Salomon, A, Pierga, J-Y, Couturier, J, d'Enghien, C D, Nos, C, Sigal-Zafrani, B, Lae, M, Fréneaux, P, Diéras, V, Thiéry, J-P, Sastre-Garau, X
Publicado 2007